Core Insights - Yangzheng Xiaojie Capsule is an innovative traditional Chinese medicine developed under the guidance of traditional Chinese medicine theory, targeting the pathological mechanisms of tumors and has been approved for use in primary liver cancer treatment in China [1][2] Group 1: Product Efficacy - Yangzheng Xiaojie Capsule integrates traditional methods with modern anti-cancer drugs, demonstrating a dual action of supporting the body while eliminating pathogens, which aligns with modern cancer treatment goals [1] - Clinical studies indicate that Yangzheng Xiaojie Capsule significantly improves the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2] - In a study on primary liver cancer, the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2] Group 2: Research and Validation - Research led by Professor Jiang Wenguo from Cardiff University found that Yangzheng Xiaojie Capsule can significantly interfere with tumor cell invasion and metastasis by inhibiting the excessive activation of the PI3K/AKT signaling pathway [1] - The same research also indicated that the capsule inhibits the activity of focal adhesion kinase, thereby suppressing tumor angiogenesis, which contributes to tumor starvation [1] Group 3: Market Expansion - Yangzheng Xiaojie Capsule has recently been approved in Thailand, marking a significant milestone in Yiling Pharmaceutical's internationalization strategy and demonstrating the practical application of traditional Chinese medicine in the "Belt and Road" initiative [4] - Yiling Pharmaceutical has successfully registered 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide, indicating strong international market recognition [4]